Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833268 · ClinicalTrials.gov registry record
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 228
- Enrollment target
NCT06833268: Completed study, sponsored by Daiichi Sankyo.
NCT06833268 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 228 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06833268 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 228 participants
- Enrollment target
Study Summary
This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic landscape.
Primary Outcome
rwPFS is defined as the interval in months between the index date until the first evidence of progression or death as documented by Flatiron.
Interventions
- OTHER No drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2025-06-16 |
What the finished NCT06833268 record still lists
NCT06833268 is an observational study that tracks outcomes without assigning an intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No drug is the first listed.
NCT06833268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06833268 about?
NCT06833268 is a clinical study titled "Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan". This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic land...
What is the current status of trial NCT06833268?
This trial is currently completed. The enrollment target is 228 participants. The study started on 2025-01-20. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06833268?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06833268?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI